ICM6011: Brain and Mind, Disorders of Supraspinal Systems

View Online

[1]

25 years since the discovery of presynaptic receptors: present knowledge and future perspectives: http://ac.els-cdn.com/S0165614796010346/1-s2.0-S0165614796010346-main.pdf?_tid=a20c5992-3c52-11e4-affe-00000aab0f26&acdnat=1410728813_db0468ec082f8cff0ef65cdbaba300ef.

[2]

Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization: http://ac.els-cdn.com/S0306452200005169/1-s2.0-S0306452200005169-main.pdf?_tid=7d42c534-3c56-11e4-8ec2-00000aacb35e&acdnat=1410730469_0edbb97e316622b92c8b7b80361ff857.

[3]

Benzodiazepines on trial: a research strategy for their rehabilitation: http://ac.els-cdn.com/0165614796100158/1-s2.0-0165614796100158-main.pdf?_tid=4055e99c-3c5d-11e4-b472-00000aacb360&acdnat=1410733373_adf79f6a94b011e6f6c582c2db5ce13d.

[4]

Blogger: Blogger Dashboard: http://www.blogger.com/home?pli=1.

[5]

Channelopathies as a genetic cause of epilepsy,:

http://ovidsp.tx.ovid.com.ezproxy.library.qmul.ac.uk/sp-3.13.0b/ovidweb.cgi?WebLinkFrameset=1&S=HHIPFPPNMFDDJOCJNCLKKHJCJCKJAA00&returnUrl=ovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.22.23%257c0%257c00019052-200304000-00009%26S%3dHHIPFPPNMFDDJOCJNCLKKHJCJCKJAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCJCKHCJMF00%2ffs004%2fovft%2flive%2fgv006%2f00019052%2f00019052-200304000-00009.pdf&filename=Channelopathies+as+a+genetic+cause+of+epilepsy.&pdf_key=FPDDNCJCKHCJMF00&pdf_index=/fs004/ovft/live/gv006/00019052/00019052-200304000-00009.

[6]

Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
http://ac.els-cdn.com/S0166223699014630/1-s2.0-S0166223699014630-main.pdf?_tid=76ab6710-3c5d-11e4-8b2e-00000aab0f27&acdnat=1410733464_1f833265d8ae90ebc3425fb58f3cac0e.

[7]

Current status and future directions in the pharmacotherapy of epilepsy:
http://ac.els-cdn.com/S016561470001974X/1-s2.0-S016561470001974X-main.pdf?_tid=c2e5d5ec-3c63-11e4-b570-00000aacb360&acdnat=1410736169_9bee4023b6baabd182302eb55b065abf.

[8]

Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals:
http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A25%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft_val_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Enzymatic%20machinery%20for%20endocannabinoid%20biosynthesis%20associated%20with%20calcium%20stores%20in%20glutamatergic%20axon%20terminals.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Nyilas&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Nyilas%2C%20Rita&rft.aucorp=&rft.date=20080130&rft.volume=28&rft.issue=5&rft.part=&rft.quarter=&rft.ssn=&rft.spage=1058&rft.epage=&rft.pages=1058-63&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/10.1523/JNEUROSCI.5102-07.2008&rft.object_id=&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&rft.eisbn=&rft_dat=%3Cmedline%3E18234884%3C/medline%3E&rft_id=info:oai/&svc.fulltext=yes.

[9]

Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals: http://www.jneurosci.org.ezproxy.library.qmul.ac.uk/content/28/5/1058.full.pdf+html.

[10]

Huntington's disease: new hope for therapeutics.: http://ac.els-cdn.com/S0166223600019974/1-s2.0-S0166223600019974-main.pdf?_tid=606a2c26-3c5c-11e4-a01e-00000aab0f02&acdnat=1410732998_957fcf339fa1c1626d376a540af8b437.

[11]

Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels - 1-s2.0-S0306452208014024-main.pdf: http://ac.els-cdn.com/S0306452208014024/1-s2.0-S0306452208014024-main.pdf?_tid=b4cf5a24-3c5d-11e4-bfa0-00000aab0f26&acdnat=1410733569_6b926f4090406133b19dd49c4a2f5015.

[12]

Iritani, S. 2007. Neuropathology of schizophrenia: A mini review. Neuropathology. 27, 6 (Dec. 2007), 604–608. DOI:https://doi.org/10.1111/j.1440-1789.2007.00798.x.

[13]

LARUELLE, M. et al. 2003. Glutamate, Dopamine, and Schizophrenia. Annals of the New York Academy of Sciences. 1003, 1 (Nov. 2003), 138–158. DOI:https://doi.org/10.1196/annals.1300.063.

[14]

LARUELLE, M. et al. 2003. Glutamate, Dopamine, and Schizophrenia. Annals of the New York Academy of Sciences. 1003, 1 (Nov. 2003), 138–158. DOI:https://doi.org/10.1196/annals.1300.063.

[15]

Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? http://ac.els-cdn.com/S0006322399001651/1-s2.0-S0006322399001651-main.pdf?_tid=16940986-3c58-11e4-8d5e-00000aab0f27&acdnat=1410731156_ea2ac6412e32b4b78b2fed3496951005.

[16]

Neurochemical markers for schizophrenia, bipolar disorder, and major depression in post-mortem brains: http://ac.els-cdn.com/S0006322304010996/1-s2.0-S0006322304010996-main.pdf?_tid=7fbcd48c-3c63-11e4-a35f-00000aab0f01&acdnat=1410736057_d16efce424c97c998802cdad24ad4012.

[17]

NMDA receptors: from genes to channels: http://ac.els-cdn.com/S0165614796800083/1-s2.0-S0165614796800083-main.pdf?_tid=c1d1c446-3c58-11e4-9397-00000aacb361&acdnat=1410731443_081c590ff059c4eb7bafa6c1f419bef9.

[18]

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease: http://ac.els-cdn.com/S0165614702020382/1-s2.0-S0165614702020382-main.pdf?_tid=c7580bd4-3c56-11e4-9515-00000aacb35e&acdnat=1410730593_5f80331cd9335e75babf21ea791761e4.

[19]

Presynaptic inhibition of elicited neurotransmitter release: http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947_43699bcaa58c68c76829e15a92277b73.

[20]

Presynaptic inhibition of elicited neurotransmitter release: http://ac.els-cdn.com/S0166223696010156/1-s2.0-S0166223696010156-main.pdf?_tid=f1e9cc4c-3c52-11e4-9b26-00000aacb35f&acdnat=1410728947_43699bcaa58c68c76829e15a92277b73.

[21]

Presynaptic receptors: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.pharmtox.38.1.201.

[22]

Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures.: http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=3&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A24%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medline&rft_val_fmt=info:ofi/fmt:kev:mtx:article&rft.genre=article&rft.atitle=Prevention%20of%20plasticity%20of%20endocannabinoid%20signaling%20inhibits%20persistent%20limbic%20hyperexcitability%20caused%20by%20developmental%20seizures.&rft.jtitle=The%20Journal%20of%20neuroscience%20:%20the%20official%20journal%20of%20the%20Society%20for%20Neuroscience&rft.btitle=&rft.aulast=Chen&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Chen%2C%20Kang&rft.aucorp=&rft.date=20070103&rft.volume=27&rft.issue=1&rft.part=&rft.quarter=&rft.ssn=&rft.spage=46&rft.epage=&rft.pages=46-58&rft.artnum=&rft.issn=&rft.eissn=1529-2401&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/&rft.object_id=&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&rft.eisbn=&rft_dat=%3Cmedline%3E17202471%3C/medline%3E&rft_id=info:oai/&svc.fulltext=yes.

[23]

Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures: http://www.jneurosci.org.ezproxy.library.qmul.ac.uk/content/27/1/46.full.pdf+html.

[24]

Schizophrenia: New Pathological Insights and Therapies - annurev.med.58.060904.084114: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.med.58.060904.084114.

[25]

Schmitz, B. et al. 2010. Assessing the unmet treatment need in partial-onset epilepsy: Looking beyond seizure control. Epilepsia. 51, 11 (Nov. 2010), 2231–2240. DOI:https://doi.org/10.1111/j.1528-1167.2010.02759.x.

[26]

Signalling via CNS cannabinoid receptors: http://ac.els-cdn.com/S0303720708000324/1-s2.0-S0303720708000324-main.pdf?_tid=2f1eb264-3c56-11e4-8497-00000aab0f6c&acdnat=1410730338_15b6a5eba718f297e2ad659d423af29f.

[27]

Solinas, M. et al. 2009. The endocannabinoid system in brain reward processes. British Journal of Pharmacology. 154, 2 (Jan. 2009), 369–383. DOI:https://doi.org/10.1038/bjp.2008.130.

[28]

Synaptic transmission: a bi-directional and self-modifiable form of cell-cell communication.: http://ac.els-cdn.com/S009286740580025X/1-s2.0-S009286740580025X-main.pdf?_tid=009b8a8e-3c51-11e4-b122-00000aacb360&acdnat=1410728112_021201c27a3e63f656189186490abaa6.

[29]

The benzodiazepine binding site of GABAA receptors: http://ac.els-cdn.com/S0165614797011188/1-s2.0-S0165614797011188-main.pdf?_tid=fbd40038-3c5c-11e4-a7b6-00000aacb362&acdnat=1410733258_871d841b33321546e4fb56e2df89c890.

[30]

The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus: http://sfx.library.qmul.ac.uk/qmsfx?frbrVersion=5&ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2013-07-10T05%3A25%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sciversesciencedirect_elsevier&rft_val_fmt=info:ofi/fmt:kev:mtx:&rft.genre=article&rft.atitle=The%20Endocannabinoid%20System%20Controls%20Key%20Epileptogenic%20Circuits%20in%20the%20Hippocampus&rft.jtitle=Neuron&rft.btitle=&rft.aulast=Monory&rft.auinit=&rft.auinit1=&rft.auinitm=&rft.ausuffix=&rft.au=Monory%2C%20Krisztina&rft.aucorp=&rft.date=2006&rft.volume=51&rft.issue=4&rft.part=&rft.quarter=&rft.ssn=&rft.spage=455&rft.epage=466&rft.pages=455-466&rft.artnum=&rft.issn=0896-6273&rft.eissn=&rft.isbn=&rft.sici=&rft.coden=&rft_id=info:doi/10.1016/j.neuron.2006.07.006&rft.object_id=&svc_val_fmt=info

:ofi/fmt:kev:mtx:sch_svc&rft.eisbn=&rft_dat=%3Csciversesciencedirect_elsevier%3ES0896-6273(06)00546-0%3C/sciversesciencedirect_elsevier%3E&rft_id=info:oai/&svc.fulltext=yes.

[31]

The endocannabinoid system controls key epileptogenic circuits in the hippocampus: http://ac.els-cdn.com/S0896627306005460/1-s2.0-S0896627306005460-main.pdf?_tid=6cce1e9e-3c54-11e4-b6b0-00000aacb360&acdnat=1410729582_711cb09225d5ffd6729eb8217664c51b.

[32]

The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies - 1-s2.0-S0165017308001045-main.pdf: http://ac.els-cdn.com/S0165017308001045/1-s2.0-S0165017308001045-main.pdf?_tid=6c088be2-3c64-11e4-8862-00000aacb35f&acdnat=1410736453_53d6ee0580d148eb6b63b36063740a15.

[33]

Volkow, N.D., Fowler, J.S., Wang, G.J. (2004) The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology, 47: 3-13.: http://ac.els-cdn.com/S0028390804002163/1-s2.0-S0028390804002163-main.pdf?_tid=d8687f4a-3c64-11e4-8ec3-00000aacb35e&acdnat=1410736635_bdf7036b1652a7f1a078294b2e6b5a2e.

[34]

Which GABAA-receptor subtypes really occur in the brain? http://ac.els-cdn.com/S0166223696800233/1-s2.0-S0166223696800233-main.pdf?_tid=75ec1f36-3c58-11e4-85ec-00000aab0f01&acdnat=1410731316_dc1140684ef448767c917608f7ef95e5.

[35]

Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.

[36]

Is there a common molecular pathway for addiction?

[37]

Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.

[38]

Neurobiology of addiction: treatment and public policy ramifications.

[39]

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

[40]

The synaptic vesicle cycle: a cascade of protein-protein interactions.